CD274 and neoplasm: For example, antibodies to programmed cell death protein 1 (PD-1) (such as nivolumab/Opdivo, pembrolizumab/Keytruda and cemiplimab/Libtayo), PD-L1 (atezolizumab/Tecentriq, avelumab/Bavencio and durvalumab/Imfinzi) and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) (ipilimumab/Yervoy) have become standard of care in tumor immunotherapy.